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Abstract
Expression of regenerating islet-derived protein 4 (REG4), a secretory protein involved in cell differentiation and
proliferation, is upregulated in inflammatory bowel diseases and in many gastrointestinal malignancies. The prognostic
significance of its expression in pancreatic ductal adenocarcinoma is unknown. Our aim was to investigate tumor tissue
and serum REG4 expression in pancreatic ductal adenocarcinoma patients. We also evaluated as a control the diagnostic
value of serum REG4 level in patients with chronic pancreatitis. Immunohistochemical expression of REG4 was
evaluated in 154 surgical specimens and serum REG4 level in 130 samples from pancreatic ductal adenocarcinoma
patients treated at Helsinki University Hospital, Finland, in 2000–2011. REG4 tissue and serum expression was assessed
in relation to clinicopathological parameters and patient survival. A chronic pancreatitis control group comprised 34
patients who underwent pancreatic resection because of suspicion of malignancy. Significant survival differences were
detectable in subgroups: in tumor stages IA–IIA, high serum REG4 level predicted worse survival (p=0.046). In patients
with grade I tumor, positive tissue REG4 expression predicted better survival (p=0.006). In multivariate analysis, neither
tissue nor serum REG4 expression was independent prognostic factors. Serum REG4 levels were higher in pancreatic
ductal adenocarcinoma than in chronic pancreatitis (p=0.002), with diagnostic sensitivity of 45% and specificity of 91%. In
logistic regression analysis, a multivariate model with REG4, CA19-9, and age provided sensitivity of 82% and specificity
of 79%. REG4 tissue expression is a prognostic marker in subgroups of pancreatic ductal adenocarcinoma patients.
Serum REG4 level might be useful in differential diagnosis between pancreatic ductal adenocarcinoma and chronic
pancreatitis.
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Introduction
With over 40,000 annual deaths in the United States,
and with a devastating overall 5-year survival under
5%,1 pancreatic ductal adenocarcinoma (PDAC) is one
of the most lethal malignancies. Radical surgical resec-
tion with or without chemotherapy is the only treat-
ment for cure but is possible in only 20% of patients.2
Despite extensive research on potential biomarkers,
since CA19-9, none has deserved a role in clinical
praxis. Identification of new biomarkers is imperative
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to predict PDAC patient outcome more precisely and
to advance our knowledge of the molecular mechan-
isms behind this disease.3,4
REG4 in cancer
The regenerating islet-derived (REG) proteins are a
group of small secretory proteins involved in regulation
of cell regeneration and proliferation.5,6 Among the
four REG families (I–IV), REG4 is the most recently
discovered member. In 2001, it was identified and iso-
lated from a complementary DNA (cDNA) library of
ulcerative colitis tissue.7 REG4 is physiologically
expressed in the colon and small intestine, where it is
highly expressed in enteroendocrine cells,8,9 but not in
the pancreatic islets.
Upregulation of REG4 expression occurs in inflam-
matory bowel diseases (IBD),7,8 but its expression is
also increased in many gastrointestinal malignancies
such as colorectal,10 gastric,11 or pancreatic cancer.12
Evidence exists that REG4 is expressed more strongly
in colorectal tumors and normal small intestine than in
normal colorectal tissue.13 Zhang et al.14 proposed that
overexpression of REG4 may be an early event in col-
orectal carcinogenesis, showing that REG4 expression
was higher in dysplastic adenomas than in normal col-
orectal mucosa. REG4 is expected to play a role also in
gastric carcinogenesis.15
REG4 can serve as a diagnostic serum marker in
colorectal cancer (CRC) with liver metastasis, but it
does not detect early tumor stages.10 Serum levels of
REG4 are significantly higher in patients with gastric
cancer than in healthy individuals at a sensitivity of
36%–73%, higher than that of CEA or CA19-9.11,16
High serum REG4 level can differentiate mucinous
ovarian cancer from other ovarian cancer subtypes and
may prove useful in follow-up of this disease.17
REG4 in pancreatic cancer
Several reports show REG4 expression in pancreatic
cancer cells to be increased above the level in normal
pancreatic cells, and REG4 to promote invasiveness
and proliferation of cancer cells.12,18,19 Moreover,
REG4-expressing pancreatic tumors tend to grow
larger, whereas knockdown of REG4 expression leads
to shrinkage of the tumor or to impaired cancer cell
growth in vivo and in vitro.12,20 More intense resistance
to radiation and chemotherapy (gemcitabine) occurs in
pancreatic cancer cell models in vivo and in vitro along
with REG4 expression.20,21 Recently, Li et al.22 demon-
strated that tissue REG1A/B expression correlates with
prognosis in PDAC, but did not report on the prognos-
tic value of tissue REG4 expression. To date, no studies
reveal the prognostic value of REG4 expression in
PDAC.
Elevated REG4 serum levels and positive immuno-
histochemical staining are present in PDAC patients,
suggesting that REG4 may serve as a diagnostic mar-
ker.12,22,23 Differential diagnosis between PDAC and
chronic pancreatitis (CP) can be challenging, especially
in patients with pancreatic mass which can prove either
benign or malignant. Reliable preoperative diagnosis
would be beneficial for patients possibly making unne-
cessary and extensive surgery avoidable. CA19-9, the
standard serum-based marker for diagnosis of
PDAC,24 has, however, diagnostic limitations, since it
can be normal in patients with localized disease or high
in patients with benign diseases including CP.
In this study, we evaluated the prognostic signifi-
cance of REG4 tissue expression and serum level in
PDAC and also analyzed serum REG4 levels in a con-
trol series comprising patients with CP.
Methods
Patients
Of the 188 patients with PDAC who underwent surgery
between 2000 and 2011 at the Department of Surgery,
Helsinki University Hospital, Finland, we excluded 34:
22 who received neoadjuvant chemotherapy, 8 who
were diagnosed with stage IV disease, and 4 in whom
stage was not reliably determinable. Median age at sur-
gery was 64 (range: 39–83) years and median follow-up
was 2.0 (range 0.2–13.1) years. The control group for
serum REG4 analysis comprised 34 patients with histo-
pathologically verified CP who, between 2000 and
2008, underwent pancreatic resection because of suspi-
cion of malignancy. Median age at surgery for this
group was 54 (range: 35–74) years. Clinical data came
from patient records, survival data from the Finnish
Population Registry, and cause of death from Statistics
Finland.
Tissue microarray blocks and immunohistochemistry
Formalin-fixed and paraffin-embedded surgical tissue
samples came from the archives of the Department of
Pathology, Helsinki University Hospital. All samples
were re-evaluated by experienced pathologists for con-
firmation of the histopathological diagnosis of PDAC.
To prepare tissue microarray blocks (TMA), represen-
tative areas of tumor samples were defined and marked
on hematoxylin- and eosin-stained slides. Six 1.0-mm-
diameter punches from both the invasive front and
from the center part of the tumor were taken from each
tumor sample with a semiautomatic tissue microarrayer
(Tissue Arrayer 1, Beecher Instruments Inc., Silver
Spring, MD, USA).25
TMA blocks were freshly cut into 4-mm sections.
After deparaffinization in xylene and rehydration
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through a gradually decreasing concentration of etha-
nol to distilled water, slides were treated in a
PreTreatment module (Lab Vision Corp., Fremont,
CA, USA) in Tris–HCl (pH 8.5) buffer for 20min at
98C for antigen retrieval. The staining procedure was
performed in an Autostainer 480 (Lab Vision) by the
Dako REAL EnVision Detection system, Peroxidase/
DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark).
Tissues were incubated with an in-house monoclonal
antibody (diluted to 1:50=50mg/mL) for 1 h at room
temperature (RT). The REG4 antibody is described in
detail elsewhere.26 Samples of colon tissue and normal
lymph node served as positive controls in each staining
series.
Scoring of samples
REG4 cytoplasmic expression in tumor cells was scored either as
negative or positive, when staining was visible. Immunostaining
was scored independently by K.S. and J.H., and the inves-
tigators were blinded to clinical data and outcome.
Differences in scoring were discussed until consensus. The
highest score of each patient was regarded as representa-
tive for analysis.
ELISA
The REG4 sandwich ELISA assays were performed
using the Human REG4 ELISA Pair Set (SEK11186,
Sino Biological Inc., Beijing, China) according to the
manufacturer’s instructions. Briefly, the primary anti-
REG4 antibody (2mg/mL in citrate-buffered saline
(CBS) buffer containing 0.05M Na2CO3, 0.05M
NaHCO3, pH 9.6) was immobilized to a 96-well plate
overnight at +4C, after which the wells were blocked
with 1% BSA in 0.05% Tris-buffered saline with Tween
(TBST) for 1h at RT. Serum samples of the 130 patients
with pancreatic carcinoma and the 34 CP controls were
diluted 1:10 in sample buffer (0.1% BSA in 0.05%
TBST) and incubated in duplicate wells (100mL per well)
for 2h at RT. The horseradish peroxidase (HRP)-conju-
gated secondary anti-REG4 antibody (0.5mg/mL in
0.5% BSA in 0.05% TBST) was allowed to bind for 1h
at RT, after which TMB substrate solution was added
and allowed to react for 20min at RT. The color reac-
tion was stopped with 1N H2SO4, and the absorbance
(450nm) was measured with Victor 1420 Multilabel
Counter (Perkin Elmer, Waltham, MA, USA).
Statistical analysis
Associations between REG4 expression and clinico-
pathological parameters were performed by Fisher’s
exact test or the linear-by-linear association test.
Survival analysis was with the Kaplan–Meier method,
and the log-rank test served to compare groups. A Cox
regression proportional hazard model was created for
univariate and multivariate survival analysis adjusted
for age, gender, stage, metastasized lymph-node ratio
(LNR) /\ 20% (cut-off /\ 20%), grade, and post-
operative adjuvant therapy. LNR at 20% is widely
used in the literature, since it is a strong prognostic fac-
tor for patient outcome.27,28 As stage and LNR are
internally correlated, a combination variable was made
for multivariate analyses. The Cox model assumption
of constant hazard ratios over time was tested by
including time-dependent covariate separately for each
testable variable at a time. A time-dependent correla-
tion factor for grade was included in the models, since
the hazard ratio for grade was not constant over time.
Interaction terms were considered.
For comparison of PDAC and CP, the Mann–
Whitney U test was used for determining the signifi-
cance of the difference in serum REG4 levels. The
serum REG4 level cut-off point for assessing survival of
PDAC was determined by the higher quarter of inter-
quartile range (IQR) of CP patients (Table 4). PDAC
patients were dichotomized into a low (\ 4.10 ng/mL)
and a high group ( 4.10 ng/mL) according to serum
REG4 level. Spearman correlation served for assessing
correlations between laboratory parameters. Receiver
operating characteristic (ROC) curves were con-
structed, and the area under the curve (AUC) values
determined to evaluate different tumor markers.
Optimal cut-off values were obtained by maximizing
Yonden’s index. Multivariate logistic regression analy-
sis allowed discovery of independent risk factors for
PDAC.
We also studied correlations between both tissue and
serum REG4 expression and CRP, CA19-9, and CEA
values by Spearman correlation. We have published the
results of the prognostic values of CRP, CA19-9, and
CEA in our PDAC patient series.29
A p value of \ 0.05 was considered significant, and
all tests were two-sided. Statistical analyses were car-
ried out with SPSS version 22.0 (IBM SPSS Statistics,
version 22.0 for Mac; SPSS, Inc., Chicago, IL, USA,
an IBM Company).
Results
REG4 is expressed in tumor cells
Positive REG4 expression was cytoplasmic with a gran-
ular distribution in tumor cells when present.
Expression was often located in apical cell goblets with
no nuclear expression evident. Staining could be evalu-
ated in 153 (99.4%) cases: 110 (71.9%) were scored as
negative and 43 (28.1%) as positive (Figure 1).
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Tissue REG4 expression is associated with tumor
histological grade
Tissue REG4 expression was associated with tumor his-
tological grade (p=0.025). Patients with positive tissue
REG4 expression more often had well-differentiated
tumors than patients with negative expression (Table 1).
Serum REG4 levels showed no significant associations
with clinicopathological parameters (Table 2).
Significant survival differences are identified in
subgroups of patients
Cancer-specific survival (CSS) was not significantly dif-
ferent for PDAC patients with positive or negative
REG4 tissue expression (log-rank p=0.496; Figure
2(a)). Five-year CSS in patients with positive REG4 tis-
sue expression was 20.1% (95% confidence interval
(CI): 7.8%–32.4%) compared to 19.7% (95% CI:
Figure 1. Tissue REG4 expression staining pattern in pancreatic ductal adenocarcinoma (PDAC): (a) negative tissue REG4
expression in PDAC and (b) positive tissue REG4 expression in PDAC. Original magnification 3400.
Figure 2. (a) Cancer-specific survival according to the Kaplan–Meier for tissue REG4 expression. (b) Cancer-specific survival
according to the Kaplan–Meier for serum REG4 level. (c) Cancer-specific survival for serum REG4 level in PDAC patients with stages
IA–IIA. (d) Cancer-specific survival for tissue REG4 expression in PDAC patients with grade I disease.
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12.1%–27.3%) for those with negative REG4 tissue
expression. By serum REG4 level, CSS did not differ
between high and low groups. Five-year CSS for
patients with high serum REG4 level was 16.2% (95%
CI: 7.4%–25.0%) and with low serum REG4 level was
25.5% (95% CI: 14.1%–36.9%) (log-rank p=0.146;
Figure 2(b)).
When divided by tumor stage, a survival benefit in a
subgroup with non-metastasized stage IA–IIA disease
was identified by serum REG4 level. Five-year survival
in PDAC patients with a high serum REG4 level was
21.3% (95% CI: 2.9%–39.7%) and with a low serum
REG4 level 52.9% (95% CI: 29.2%–76.6%) (log-rank
p=0.046; Figure 2(c)). Positive tissue REG4 expression
predicted better prognosis when compared with nega-
tive tissue REG4 expression in PDAC patients with
grade 1 disease (5-year CSS 36.4% vs 0.0%; log-rank
p=0.006; Figure 2(d)). No such difference was detect-
able in PDAC patients with grade II–III disease.
Unfortunately, we had only 18 grade I patients.
In univariate analysis, neither tissue REG4 expression
(hazard ratio (HR)=0.87, 95% CI: 0.59%–1.29%,









\65 34 (30.9) 9 (20.9) 0.238
65 76 (69.1) 34 (79.1)
Gender
Male 63 (57.3) 21 (48.8) 0.371
Female 47 (42.7) 22 (51.2)
T
1 7 (6.4) 4 (9.3) 0.892
2 30 (27.3) 10 (23.3)
3 72 (65.5) 27 (62.8)
4 1 (0.9) 2 (4.7)
N
0 35 (31.8) 13 (30.2) 1.000
1 75 (68.2) 30 (69.8)
Stage (AJCC)
IA 7 (6.4) 3 (7.0) 0.640
IB 13 (11.8) 4 (9.3)
IIA 15 (13.6) 5 (11.6)
IIB 74 (67.3) 29 (67.4)
III 1 (0.9) 2 (4.7)
Lymph-node ratio
\20% 85 (77.3) 33 (78.6) 1.000
20% 25 (22.7) 9 (21.4)
Missing 1
Histological grade
1 7 (6.4) 11 (26.2) 0.025
2 84 (76.4) 25 (59.5)
3 19 (17.3) 6 (14.3)
Missing 0 1
Perineural invasion
Yes 75 (81.5) 26 (68.4) 0.111
No 17 (18.5) 12 (31.6)
Missing 18 5
Perivascular invasion
Yes 33 (37.1) 10 (27.8) 0.407
No 56 (62.9) 26 (72.2)
Missing 21 7
REG4: regenerating islet-derived protein 4; AJCC: American Joint
Committee on Cancer.
Fisher’s exact test served for 2 3 2 tables and the linear-by-linear
association test for tables with more than two rows. Missing data
excluded from analysis. AJCC 7th edition.
Table 2. Association of serum REG4 levels and
clinicopathological parameters.
Serum REG4 level
n (%) Low (\4.1 ng/mL)
60 (46.2)




\65 16 (26.7) 23 (32.9) 0.565
65 44 (73.3) 47 (67.1)
Gender
Male 32 (53.3) 44 (62.9) 0.289
Female 28 (46.7) 26 (37.1)
T
1 4 (6.7) 3 (4.3) 0.203
2 19 (31.7) 16 (22.9)
3 36 (60.0) 49 (70.0)
4 1 (1.7) 2 (2.9)
N
0 18 (30.0) 19 (27.1) 0.846
1 42 (70.0) 51 (62.9)
Stage (AJCC)
IA 3 (5.0) 3 (4.3) 0.844
IB 7 (11.7) 7 (10.0)
IIA 7 (11.7) 10 (14.3)
IIB 42 (70.0) 48 (68.6)
III 1 (1.7) 2 (2.9)
Lymph-node ratio
\20% 48 (80.0) 51 (73.9) 0.531
20% 12 (20.0) 18 (26.1)
Missing 0 1
Histological grade
1 9 (15.3) 6 (8.6) 0.132
2 43 (72.9) 50 (71.4)
3 7 (11.9) 14 (20.0)
Missing 1 0
Perineural invasion
Yes 38 (73.1) 46 (79.3) 0.504
No 14 (26.9) 12 (20.7)
Missing 8 12
Perivascular invasion
Yes 19 (38.0) 18 (32.1) 0.547
No 31 (62.0) 38 (67.9)
Missing 10 14
REG4: regenerating islet-derived protein 4; AJCC: American Joint
Committee on Cancer.
Fisher’s exact test served for 2 3 2 tables and the linear-by-linear
association test for tables with more than two rows. Missing data
excluded from analysis. AJCC 7th edition.
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p=0.496) nor serum REG4 level (HR=1.33, 95% CI:
0.90%–1.95%, p=0.148) associated significantly with
survival in PDAC (Table 3). However, positive tissue
REG4 expression was a protective factor for survival in
PDAC patients with grade I disease as compared to
negative expression (HR=0.21, 95% CI: 0.07%–0.70%,
p=0.011; data not shown).
In multivariate analysis adjusted for age, gender,
stage, LNR, grade, and postoperative adjuvant che-
motherapy, neither tissue REG4 expression nor serum
REG4 level predicted survival significantly (HR=0.87,
95% CI: 0.55%–1.35%, p=0.528 and HR=1.18, 95%
CI: 0.79%–1.78%, p=0.417, respectively). However,
there occurred a significant interaction between grade
and tissue REG4 expression. The interaction model
also suggests that positive tissue REG4 expression was
a protective factor for survival in patients with grade I
disease (HR=0.14, 95% CI: 0.03%–0.68%, p=0.015)
Serum REG4 levels are higher in PDAC than in CP
Serum REG4 levels in PDAC were assessed in 130
patients. Median for serum REG4 level in PDAC was
4.90 (range: 1.0–59.1) ng/mL. Serum REG4 levels were
significantly higher in PDAC patients than in patients
with CP (median 4.90 vs 3.05 ng/mL; p=0.002, Mann–
Whitney test; Figure 3 and Table 4). Serum REG4 lev-
els in different stages of PDAC are summarized in
Table 4. We found no significant differences in serum
REG4 levels between tumor stages (data not shown).
REG4 expression is not correlated with CRP values
No significant correlation existed between tissue REG4
expression and serum REG4 level in PDAC (p=0.289,
correlation coefficient (r)=0.094, standard error
(SE)=0.100). We also analyzed the correlation in
PDAC patients between C-reactive protein (CRP)
Table 3. Cox univariate analysis of relative risk of death from
pancreatic ductal adenocarcinoma by REG4 tissue (n=153) and
serum (n=130) expression.
Covariate n HR 95% CI p value
REG4 tissue expression
Negative 110 1.00
Positive 43 0.87 0.59–1.29 0.496
REG4 serum expression
Low 60 1.00
High 70 1.33 0.90–1.95 0.148
Age at operation (years)
\65 43 1.00
65 110 1.21 0.82–1.79 0.346
Gender
Male 84 1.00
Female 69 0.92 0.65–1.31 0.650
T
1 11 1.00
2 40 0.85 0.40–1.78 0.657
3 99 1.45 0.73–2.89 0.291
4 3 3.80 1.01–14.30 0.049
N
0 48 1.00
1 105 1.65 1.11–2.44 0.012
Grade
1 18 1.00
2 109 1.24 0.71–2.14 0.449




IB 14 0.74 0.30–1.85 0.517
IIA 17 1.06 0.45–2.50 0.901
IIB 90 1.54 0.75–3.17 0.244
III 3 4.11 1.07–15.81 0.040
Stage and LNR
IA, IB, and IIA 47 1.00
IIB, III, and LNR \20% 72 1.40 0.92–2.14 0.116
IIB, III and LNR .20% 34 2.91 1.79–4.74 \0.001
Perivascular invasion
No 82 1.00









Yes 80 0.78 0.55–1.11 0.169
Missing 1
REG4: regenerating islet-derived protein 4; HR: hazard ratio; CI:
confidence interval; LNR: metastasized lymph-node ratio.
Stage and LNR covariate was formed to cover both in multivariate
analysis.
Figure 3. Serum REG4 levels are significantly higher in
pancreatic ductal adenocarcinoma (PDAC) than in chronic
pancreatitis (CP) (median 4.90 vs 3.05 ng/mL; p=0.002, Mann–
Whitney test).
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values and tissue REG4 expression and serum REG4
levels, but no significant correlation was detectable
(p=0.885, r=0.013, SE=0.096 and p=0.318, r=0.089,
SE=0.088, respectively). In addition, no correlation
was detectable between CRP values and serum REG4
levels when divided by tumor histological grade. Serum
REG4 level correlated with CEA level (p=0.036,
r=0.188, SE=0.088), but not with CA19-9 (p=0.975,
r=0.003, SE 0.092). CA19-9 and CEA levels did not
differ significantly between low and high serum REG4
level groups (p=0.444, and p=0.097; data not shown).
Serum REG4 increases diagnostic accuracy
ROC analysis was performed to evaluate and compare
the diagnostic accuracy of REG4, CA19-9, and CEA.
AUC value for REG4 was 0.675 (95% CI: 0.587%–
0.763%, p=0.002); for CA19-9, 0.806 (95% CI:
0.737%–0.874%, p\0.001); and for CEA, 0.544 (95%
CI: 0.437%–0.650%, p=0.460) (Figure 4). Serum
REG4 sensitivity was 45%, and specificity was 91%
with optimal cut-off value 5.3 ng/mL. For serum
CA19-9, sensitivity of 81% and specificity of 74% were
achieved with an optimal cut-off value of 17 kU/L.
In a multivariate logistic regression model adjusted
for age, values for serum REG4 and CA19-9 were sig-
nificant and independent risk factors for PDAC
(Table 5), suggesting that their combination may be
able to improve diagnostic accuracy. The ROC curve
of the logistic regression model achieved an AUC of
0.867 (95% CI: 0.804%–0.930%, p\0.001), which
numerically exceeds REG4 or CA19-9 AUCs alone
(Figure 4). At the optimal cut-off, this yields a sensitiv-
ity of 85% and specificity of 79%.
Table 4. Serum REG4 levels in pancreatic ductal
adenocarcinoma and chronic pancreatitis.
REG4 level (ng/mL) p value*



































REG4: regenerating islet-derived protein 4; IQR: interquartile range;
PDAC: pancreatic ductal adenocarcinoma.
*Mann–Whitney U test for comparing serum REG4 levels in different
stages of PDAC and chronic pancretitis. Serum REG4 levels did not
differ significantly between different stages of PDAC (data not shown).
Figure 4. Comparison of serum REG4, CA19-9, CEA, and
calculated probability of cancer with receiver operating
characteristic (ROC) analysis from 130 patients with pancreatic
ductal adenocarcinoma; 34 patients with chronic pancreatitis
served as controls.
AUC: area under curve; SE: standard error.
Table 5. Multivariate logistic regression analysis for risk of
PDAC.
Variable OR 95% CI p value
Age 1.10 1.04–1.16 \0.001
Serum REG4 level 7.88 1.13–54.92 0.037
Serum CA19-9 level 3.06 1.62–5.81 \0.001
PDAC: pancreatic ductal adenocarcinoma; OR: odds ratio; CI:
confidence interval; REG4: regenerating islet-derived protein 4.
Logarithmic transformation performed for REG4 and CA19-9 variables.
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Discussion
We demonstrate that REG4 expression could serve as a
prognostic factor in PDAC patients with early disease
and in those with well-differentiated tumors. We also
identified significant differences in serum REG4 levels
between PDAC and CP. Both REG4 and CA19-9 pro-
vided independent diagnostic information. This sug-
gests that serum REG4 might prove to be a diagnostic
marker in PDAC.
To date, no reports show the prognostic significance
of REG4 expression in PDAC. Li et al.22 recently
reported that low REG1A/B tissue expression is a mar-
ker of poor prognosis in PDAC. However, REG1A/B
is normally expressed by the exocrine pancreas, and
REG4 is not.7 Moreover, the REG4 gene is on chromo-
some 1, whereas other REG genes are on chromosome
2.7,8 One can speculate that the biological functions of
these proteins are distinct from each other because they
are located on different chromosomes and encoded by
different transcription factors.
REG4 has been under study in other gastrointestinal
cancers as well. High tissue REG4 expression is a mar-
ker of poor prognosis in CRC by immunohisto-
chemistry30 and by mRNA expression.31 However,
Kaprio et al.32 showed positive REG4 tissue expression
to be a marker of better prognosis in non-mucinous
CRC. High tissue REG4 expression predicts poor sur-
vival in gastric cancer,33 in which it can also promote
peritoneal metastasis.34 In gallbladder cancer, positive
tissue REG4 expression is associated with favorable
prognosis.35 In our study, 5-year CSS did not differ sig-
nificantly in PDAC patients with positive or negative
tissue REG4 expression, or with high or low serum
REG4 level.
An intriguing finding is that patients with early stage
(IA–IIA) disease showed better prognosis with lower
serum REG4 levels. What animal models and cell cul-
tures demonstrate is that pancreatic tumors tend to
grow larger when REG4 expression is intro-
duced.12,18–20 It is possible that negative or low-REG4-
expressing pancreatic tumors grow slower and are bet-
ter differentiated also in humans. We show that posi-
tive tissue REG4 expression predicts better prognosis
in PDAC patients with histological grade I disease. Li
et al.22 came to the same conclusion for tissue REG1A/
B expression. They also showed that higher levels of
REG1A/B were associated with lower cancer-cell dif-
ferentiation grade. The cut-off value of serum REG4 at
4.10 ng/mL for survival estimation was determined to
find the optimal value, which both differentiates
PDAC from CP and predicts prognosis in PDAC.
In addition to malignancies, REG4 expression is
upregulated in inflammatory processes, such as IBD.7,8
In experimental pancreatitis in mice, increased REG4
expression can protect against acinar cell necrosis,36
suggesting that REG4 may have anti-inflammatory fea-
tures. We can speculate that in well-differentiated pan-
creatic tumors, REG4 expression may have a protective
function against dedifferentiation. However, we found
no correlation between different histological grades, or
between REG4 and CRP values. The possible anti-
inflammatory role of REG4 needs further study.
We demonstrate that between PDAC and CP serum
REG4 levels differ significantly. All patients with CP
had undergone surgery to exclude malignancy, but his-
topathology of the surgical samples confirmed CP. To
our knowledge, this is the first study to report such a
significant difference. Li et al.22 found that REG1A/B
functions better as a diagnostic marker in PDAC than
does REG4, but REG1A/B levels did not differ signifi-
cantly between CP and healthy controls. The cut-off
level for REG4 in our series was somewhat higher than
in other studies. Takehara et al.12 used a cut-off point
of 4.53 ng/mL but reported neither their sensitivity nor
specificity. Takayama et al.23 used a cut-off point of
3.49 ng/mL with 94.0% sensitivity and 64.0% specifi-
city. However, they included also patients with stage
IV PDAC, and their comparison of REG4 levels was
between levels in PDAC and in healthy subjects. We
excluded stage IV patients and compared serum REG4
levels between PDAC and CP, which is a clinically
more relevant comparison. This probably explains the
differing results between these studies.
In gastric cancer, the usefulness of REG4 as a diag-
nostic marker has been under study, showing that REG4
seems to function better than does CEA or CA19-9.16
Lehtinen et al.17 reported recently that REG4 expression
could serve as a diagnostic serum biomarker for differen-
tiating mucinous ovarian cancer from other epithelial
ovarian cancer subtypes, and that it could be useful dur-
ing follow-up. They detected that in mucinous ovarian
carcinomas, serum REG4 levels were nearly 40 times
higher than in serous ovarian carcinomas before surgery
and that serum REG4 levels declined rapidly after sur-
gery. It would be intriguing to study REG4 levels during
follow-up of PDAC.
Data collection was comprehensive, but some impor-
tant clinicopathological parameters were unavailable.
The TMA technique allows analysis of large patient
cohorts compared to analysis of whole-tissue blocks.
Considerably smaller areas of tumors are evaluated by
TMA, but the potential sampling error is reduced by
taking core samples from different parts of the tumor.
Less than 1% of specimens were lost for technical rea-
sons. Because of the extended time-course of data
collection, some serum samples were unavailable for
serum analyses. The strength of this study is a quite
large patient cohort with long follow-up. However, the
protective role of positive tissue REG4 expression in
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grade I PDAC patients was not strong, since the low
number of patients in this subgroup limited its signifi-
cance. The clinical setting was relevant, taking into
account that CP patients, because their diagnosis could
not be determined by preoperative testing, underwent
extensive surgery.
Conclusion
We demonstrate that REG4 expression could prove
useful as a prognostic marker in PDAC in subgroups
of patients but also serve as a diagnostic serum marker
in addition to CA19-9. Validation of REG4 expression
as a prognostic marker requires further study.
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